Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$712M |
| 2 |
PepsiCo
PEP
|
+$669M |
| 3 |
State Street Consumer Staples Select Sector SPDR ETF
XLP
|
+$635M |
| 4 |
Walmart Inc
WMT
|
+$544M |
| 5 |
Palantir
PLTR
|
+$538M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.34B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.65B |
| 3 |
Tesla
TSLA
|
+$1.45B |
| 4 |
Invesco QQQ Trust
QQQ
|
+$1.01B |
| 5 |
Apple
AAPL
|
+$833M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.48% |
| 2 | Financials | 7.27% |
| 3 | Consumer Discretionary | 6.82% |
| 4 | Communication Services | 5.06% |
| 5 | Healthcare | 4.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FBLA
4026
FB Bancorp
FBLA
$248M
| $302K | ﹤0.01% |
25,144
-16,473
| -40% | -$195K |
|
4027
Anika Therapeutics
ANIK
$258M
| $301K | ﹤0.01% |
32,074
-3,316
| -9% | -$31.7K |
|
4028
Park-Ohio Holdings
PKOH
$575M
| $301K | ﹤0.01% |
14,188
-2,871
| -17% | -$55K |
|
4029
Tonix Pharmaceuticals
TNXP
$160M
| $301K | ﹤0.01% |
12,466
-833
| -6% | -$30.9K |
|
4030
Sky Harbour Group
SKYH
$369M
| $301K | ﹤0.01% |
30,477
-7,211
| -19% | -$73.6K |
|
|
MTA
4031
Metalla Royalty & Streaming
MTA
$688M
| $301K | ﹤0.01% |
47,351
+351
| +0.7% | +$1.66K |
|
|
DBVT
4032
DBV Technologies
DBVT
$799M
| $300K | ﹤0.01% |
30,005
+23,394
| +354% | +$228K |
|
4033
The Oncology Institute
TOI
$486M
| $300K | ﹤0.01% |
85,847
-17,823
| -17% | -$61.1K |
|
4034
Lifecore Biomedical
LFCR
$166M
| $299K | ﹤0.01% |
40,572
-7,203
| -15% | -$54.5K |
|
4035
Benitec Biopharma
BNTC
$402M
| $299K | ﹤0.01% |
21,283
-5,657
| -21% | -$72.2K |
|
4036
C&F Financial
CFFI
$268M
| $299K | ﹤0.01% |
4,442
-910
| -17% | -$61.8K |
|
4037
Nkarta
NKTX
$150M
| $298K | ﹤0.01% |
144,147
-136,165
| -49% | -$280K |
|
4038
Asure Software
ASUR
$230M
| $298K | ﹤0.01% |
36,324
-4,733
| -12% | -$42.3K |
|
4039
Utah Medical Products
UTMD
$225M
| $297K | ﹤0.01% |
4,711
-772
| -14% | -$45.7K |
|
4040
Rocky Brands
RCKY
$366M
| $296K | ﹤0.01% |
9,945
-1,868
| -16% | -$50.2K |
|
4041
ProShares Short VIX Short-Term Futures ETF
SVXY
$228M
| $296K | ﹤0.01% |
5,810
| – | – |
|
4042
Critical Metals Corp
CRML
$806M
| $296K | ﹤0.01% |
47,578
-130,095
| -73% | -$667K |
|
4043
DMC Global
BOOM
$138M
| $296K | ﹤0.01% |
34,995
-9,208
| -21% | -$69K |
|
4044
eHealth
EHTH
$42.2M
| $296K | ﹤0.01% |
68,580
+1,052
| +2% | +$4.04K |
|
|
LNKB
4045
DELISTED
LINKBANCORP
LNKB
| $295K | ﹤0.01% |
41,410
-3,182
| -7% | -$23.1K |
|
4046
Douglas Elliman
DOUG
$154M
| $295K | ﹤0.01% |
103,163
-21,184
| -17% | -$55.6K |
|
4047
SELLAS Life Sciences
SLS
$1.97B
| $294K | ﹤0.01% |
182,680
+9,877
| +6% | +$17.6K |
|
|
OLPX
4048
DELISTED
Olaplex Holdings
OLPX
| $293K | ﹤0.01% |
223,796
-65,560
| -23% | -$94K |
|
|
DDL
4049
Dingdong
DDL
$562M
| $292K | ﹤0.01% |
141,263
| – | – |
|
4050
The Joint Corp
JYNT
$118M
| $292K | ﹤0.01% |
30,612
-6,434
| -17% | -$69.8K |
|
Similar funds
Barclays's Q3 2025 Portfolio in Review
As of Q3 2025, Barclays held 5,800 positions worth $461B, up 5.7% from $436B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Barclays's Q3 2025 filing shows 615 new, 1,596 increased, 2,751 reduced and 340 closed positions. Its largest new stake was Paramount Skydance Corp: 13,646,704 shares worth $258M. The largest sale was NVIDIA, an estimated $2.34B.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
- Barclays's largest Q3 2025 buy was Paramount Skydance Corp: 13,646,704 shares worth $258M.
- Barclays added most to iShares iBoxx $ High Yield Corporate Bond ETF in Q3 2025, an estimated $712M increase.
- Barclays's biggest Q3 2025 reduction was NVIDIA, cutting an estimated $2.34B.
- Barclays fully exited Blueprint Medicines in Q3 2025, selling an estimated $200M.
- Barclays's ten largest holdings make up 40% of its $461B portfolio in Q3 2025.
- Barclays opened 615 new positions and closed 340 in Q3 2025.
- Barclays's portfolio value rose 5.7% quarter-over-quarter to $461B.
Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.